CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation

• Status: Recruiting
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: All

Summary

For acute leukemia patients with early relapse after allogeneic stem cell transplantation, the overall outcome is poor. In this study, we evaluate the treatment outcome and safety of chemotherapy with Cladribine, cytarabine and mitoxantrone followed by peripheral stem cell support from the original donor.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Cladribine; Cytarabine; Mitoxantrone

Criteria

Inclusion Criteria:

• patients with acute leukemia relapsed within 6 months after previous allo-HSCT

• no active GVHD

• mobilized PBSC from the original donor available

Exclusion Criteria:

• ECOG >=3

• liver function/renal function damage (over 2 X upper normal range)

• active infection including CMV and EBV